Q-omics provides the consensus-scored ADH5P5 profile across patient tissues and cancer cell-line models. ADH5P5 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ADH5P5 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, ADH5P5 RNA expression shows 3,522 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and HNSC as cancer lineages where ADH5P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADH5P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADH5P5 survival associations across molecular data types. ADH5P5 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADH5P5 RNA expression–survival associations across cancer types. High ADH5P5 expression shows unfavorable associations in STAD, LUSC, CHOL and KIRP, but favorable associations in KIRC and UCS. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for ADH5P5 RNA expression.
This table summarizes ADH5P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ADH5P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADH5P5 shows lower tumor expression in HNSC, KIRC and READ and higher tumor expression in LIHC and LUSC. The HNSC box plot shows higher ADH5P5 RNA expression in normal versus tumor tissue (log2 FC = −0.085, t-test p = .008).
This table shows molecular features associated with ADH5P5 in patient tissues and cancer cell lines. In patient samples, ADH5P5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
